{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T05:04:25Z","timestamp":1771131865764,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,14]]},"DOI":"10.7759\/cureus.103620","type":"journal-article","created":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T04:38:06Z","timestamp":1771130286000},"source":"Crossref","is-referenced-by-count":0,"title":["Intravitreal Brolucizumab Use for Retinal Vascular Diseases in Resource-Constrained Settings: A Retrospective Study From Bangladesh"],"prefix":"10.7759","author":[{"given":"Muhammad","family":"Moniruzzaman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Azzam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mst Sayedatun","family":"Nessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abrar","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tangil","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizanur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-013-0993-5","article-title":"Ocular neovascularization","volume":"91","author":"Campochiaro PA","year":"2013","unstructured":"Campochiaro PA. Ocular neovascularization. J Mol Med (Berl). 2013, 91:311-21. 10.1007\/s00109-013-0993-5","journal-title":"J Mol Med (Berl)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052247","article-title":"Prevalence of blindness and its determinants in Bangladeshi adult population: results from a national cross-sectional survey","volume":"12","author":"Shakoor SA","year":"2022","unstructured":"Shakoor SA, Rahman M, Hossain AH, Moniruzzaman M, Bhuiyan MR, Hakim F, Zaman MM. Prevalence of blindness and its determinants in Bangladeshi adult population: results from a national cross-sectional survey. BMJ Open. 2022, 12:e052247. 10.1136\/bmjopen-2021-052247","journal-title":"BMJ Open"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5114\/ceji.2016.63132","article-title":"The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy","volume":"41","author":"Po\u017carowska D","year":"2016","unstructured":"Po\u017carowska D, Po\u017carowski P. The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy. Cent Eur J Immunol. 2016, 41:311-6. 10.5114\/ceji.2016.63132","journal-title":"Cent Eur J Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S259298","article-title":"Current and future anti-VEGF agents for neovascular age-related macular degeneration","volume":"13","author":"Kaiser SM","year":"2021","unstructured":"Kaiser SM, Arepalli S, Ehlers JP. Current and future anti-VEGF agents for neovascular age-related macular degeneration. J Exp Pharmacol. 2021, 13:905-12. 10.2147\/JEP.S259298","journal-title":"J Exp Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012208.pub2","article-title":"Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration","volume":"5","author":"Li E","year":"2020","unstructured":"Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2020, 5:CD012208. 10.1002\/14651858.CD012208.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/life13051098","article-title":"Update on the management of diabetic retinopathy: anti-VEGF agents for the prevention of complications and progression of nonproliferative and proliferative retinopathy","volume":"13","author":"Bahr TA","year":"2023","unstructured":"Bahr TA, Bakri SJ. Update on the management of diabetic retinopathy: anti-VEGF agents for the prevention of complications and progression of nonproliferative and proliferative retinopathy. Life (Basel). 2023, 13:1098. 10.3390\/life13051098","journal-title":"Life (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2174\/1573399811666150615151324","article-title":"Anti-VEGF therapy for retinal vein occlusions","volume":"17","author":"Campa C","year":"2016","unstructured":"Campa C, Alivernini G, Bolletta E, Parodi MB, Perri P. Anti-VEGF therapy for retinal vein occlusions. Curr Drug Targets. 2016, 17:328-36. 10.2174\/1573399811666150615151324","journal-title":"Curr Drug Targets"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051049","article-title":"Anti-VEGF-resistant retinal diseases: a review of the latest treatment options","volume":"10","author":"Wallsh JO","year":"2021","unstructured":"Wallsh JO, Gallemore RP. Anti-VEGF-resistant retinal diseases: a review of the latest treatment options. Cells. 2021, 10:1049. 10.3390\/cells10051049","journal-title":"Cells"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.720345","article-title":"Short-term efficacy and safety outcomes of brolucizumab in the real-life clinical practice","volume":"12","author":"Montesel A","year":"2021","unstructured":"Montesel A, Bucolo C, Sallo FB, Eandi CM. Short-term efficacy and safety outcomes of brolucizumab in the real-life clinical practice. Front Pharmacol. 2021, 12:720345. 10.3389\/fphar.2021.720345","journal-title":"Front Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration","volume":"128","author":"Dugel PU","year":"2021","unstructured":"Dugel PU, Singh RP, Koh A, et al.. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021, 128:89-99. 10.1016\/j.ophtha.2020.06.028","journal-title":"Ophthalmology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/08820538.2023.2271095","article-title":"Safety and efficacy of brolucizumab in the treatment of diabetic macular edema and diabetic retinopathy: a systematic review and meta-analysis","volume":"39","author":"Abu Serhan H","year":"2024","unstructured":"Abu Serhan H, Taha MJ, Abuawwad MT, et al.. Safety and efficacy of brolucizumab in the treatment of diabetic macular edema and diabetic retinopathy: a systematic review and meta-analysis. Semin Ophthalmol. 2024, 39:251-60. 10.1080\/08820538.2023.2271095","journal-title":"Semin Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15242","article-title":"Efficacy and safety of brolucizumab in age-related macular degeneration: a systematic review of real-world studies","volume":"101","author":"Baumal CR","year":"2023","unstructured":"Baumal CR, S\u00f8rensen TL, Karcher H, et al.. Efficacy and safety of brolucizumab in age-related macular degeneration: a systematic review of real-world studies. Acta Ophthalmol. 2023, 101:123-39. 10.1111\/aos.15242","journal-title":"Acta Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel PU","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, et al.. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020, 127:72-84. 10.1016\/j.ophtha.2019.04.017","journal-title":"Ophthalmology"},{"key":"ref14","article-title":"Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment","volume":"94","author":"Burroughs VJ","year":"2002","unstructured":"Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc. 2002, 94:1-26.","journal-title":"J Natl Med Assoc"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/ph18111620","article-title":"Effectiveness, safety, and real-world experience of brolucizumab: a systematic review","volume":"18","author":"Alali NM","year":"2025","unstructured":"Alali NM, Aljahdali A, AlBalawi HB, et al.. Effectiveness, safety, and real-world experience of brolucizumab: a systematic review. Pharmaceuticals (Basel). 2025, 18:1620. 10.3390\/ph18111620","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref16","unstructured":"Out-of-pocket expenditure (% of current health expenditure) - Bangladesh. (2025). Accessed. January 22, 2026: https:\/\/data.worldbank.org\/indicator\/SH.XPD.OOPC.CH.ZS?locations=BD."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.12.004","article-title":"Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema","volume":"115","author":"Browning DJ","year":"2008","unstructured":"Browning DJ, Glassman AR, Aiello LP, et al.. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology. 2008, 115:1366-71.e1. 10.1016\/j.ophtha.2007.12.004","journal-title":"Ophthalmology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-022-00558-z","article-title":"OCT macular volume as a predictor of vascular leakage in uveitis","volume":"11","author":"Chen X","year":"2022","unstructured":"Chen X, Zhu W, Li X. OCT macular volume as a predictor of vascular leakage in uveitis. Ophthalmol Ther. 2022, 11:1913-24. 10.1007\/s40123-022-00558-z","journal-title":"Ophthalmol Ther"},{"key":"ref19","unstructured":"Label. BEOVU- brolucizumab injection, solution. (2025). Accessed: November 1, 2025: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=5d1dc1fa-a2d3-46ed-9e9a-c1a036590d3d."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14659","article-title":"A novel excel sheet conversion tool from Snellen fraction to LogMAR including 'counting fingers', 'hand movement', 'light perception' and 'no light perception' and focused review of literature of low visual acuity reference values","volume":"99","author":"Moussa G","year":"2021","unstructured":"Moussa G, Bassilious K, Mathews N. A novel excel sheet conversion tool from Snellen fraction to LogMAR including 'counting fingers', 'hand movement', 'light perception' and 'no light perception' and focused review of literature of low visual acuity reference values. Acta Ophthalmol. 2021, 99:e963-5. 10.1111\/aos.14659","journal-title":"Acta Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/APO.0000000000000602","article-title":"Review on the safety and efficacy of brolucizumab for neovascular age-related macular degeneration from major studies and real-world data","volume":"12","author":"Radke NV","year":"2023","unstructured":"Radke NV, Mohamed S, Brown RB, et al.. Review on the safety and efficacy of brolucizumab for neovascular age-related macular degeneration from major studies and real-world data. Asia Pac J Ophthalmol (Phila). 2023, 12:168-83. 10.1097\/APO.0000000000000602","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ph13100264","article-title":"Current pharmacological treatment options for central serous chorioretinopathy: a review","volume":"13","author":"Nicol\u00f2 M","year":"2020","unstructured":"Nicol\u00f2 M, Desideri LF, Vagge A, Traverso CE. Current pharmacological treatment options for central serous chorioretinopathy: a review. Pharmaceuticals (Basel). 2020, 13:264. 10.3390\/ph13100264","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2728","article-title":"Evaluation of optical coherence tomography retinal thickness parameters for use in clinical trials for neovascular age-related macular degeneration","volume":"50","author":"Keane PA","year":"2009","unstructured":"Keane PA, Liakopoulos S, Jivrajka RV, Chang KT, Alasil T, Walsh AC, Sadda SR. Evaluation of optical coherence tomography retinal thickness parameters for use in clinical trials for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009, 50:3378-85. 10.1167\/iovs.08-2728","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.124.2.193","article-title":"Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography","volume":"124","author":"Chan A","year":"2006","unstructured":"Chan A, Duker JS, Ko TH, Fujimoto JG, Schuman JS. Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography. Arch Ophthalmol. 2006, 124:193-8. 10.1001\/archopht.124.2.193","journal-title":"Arch Ophthalmol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_902_17","article-title":"Optical coherence tomography: a guide to interpretation of common macular diseases","volume":"66","author":"Bhende M","year":"2018","unstructured":"Bhende M, Shetty S, Parthasarathy MK, Ramya S. Optical coherence tomography: a guide to interpretation of common macular diseases. Indian J Ophthalmol. 2018, 66:20-35. 10.4103\/ijo.IJO_902_17","journal-title":"Indian J Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.64.5.28","article-title":"Mechanisms of acquired resistance to anti-VEGF therapy for neovascular eye diseases","volume":"64","author":"Sharma D","year":"2023","unstructured":"Sharma D, Zachary I, Jia H. Mechanisms of acquired resistance to anti-VEGF therapy for neovascular eye diseases. Invest Ophthalmol Vis Sci. 2023, 64:28. 10.1167\/iovs.64.5.28","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2024.102152","article-title":"Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario - the BRADIR study","volume":"36","author":"Chakraborty D","year":"2024","unstructured":"Chakraborty D, Sharma A, Mondal S, et al.. Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario - the BRADIR study. Am J Ophthalmol Case Rep. 2024, 36:102152. 10.1016\/j.ajoc.2024.102152","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101197","article-title":"Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: a real-world case series","volume":"24","author":"Chakraborty D","year":"2021","unstructured":"Chakraborty D, Sheth JU, Boral S, Sinha TK. Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: a real-world case series. Am J Ophthalmol Case Rep. 2021, 24:101197. 10.1016\/j.ajoc.2021.101197","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-38173-y","article-title":"Real-world study to evaluate the efficacy and safety of intravitreal brolucizumab for refractory neovascular age-related macular degeneration","volume":"13","author":"Yeom H","year":"2023","unstructured":"Yeom H, Kwon HJ, Kim YJ, Lee J, Yoon YH, Lee JY. Real-world study to evaluate the efficacy and safety of intravitreal brolucizumab for refractory neovascular age-related macular degeneration. Sci Rep. 2023, 13:11400. 10.1038\/s41598-023-38173-y","journal-title":"Sci Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S425709","article-title":"Efficacy, safety, and durability of brolucizumab: an 8-month post-marketing surveillance analysis","volume":"17","author":"Saba NJ","year":"2023","unstructured":"Saba NJ, Walter SD. Efficacy, safety, and durability of brolucizumab: an 8-month post-marketing surveillance analysis. Clin Ophthalmol. 2023, 17:2791-802. 10.2147\/OPTH.S425709","journal-title":"Clin Ophthalmol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2015.48","article-title":"Defining response to anti-VEGF therapies in neovascular AMD","volume":"29","author":"Amoaku WM","year":"2015","unstructured":"Amoaku WM, Chakravarthy U, Gale R, et al.. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015, 29:721-31. 10.1038\/eye.2015.48","journal-title":"Eye (Lond)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/406721-intravitreal-brolucizumab-use-for-retinal-vascular-diseases-in-resource-constrained-settings-a-retrospective-study-from-bangladesh","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T04:38:07Z","timestamp":1771130287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/406721-intravitreal-brolucizumab-use-for-retinal-vascular-diseases-in-resource-constrained-settings-a-retrospective-study-from-bangladesh"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.103620","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,14]]}}}